The enhanced enforcement against corruption in the pharmaceutical and healthcare sector since June 2013 has led to intensified investigations into various multinational pharmaceutical companies in China. Against this backdrop, the
Avoiding the pharma blacklist
New Provisions creating a nationwide blacklist show the seriousness of the campaign against bribery and corruption. Here is what businesses should know about the new regulation
By
clpstaff
& clp articles